# Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

> **NCT04847232** · PHASE3 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 2690 (actual)

## Conditions studied

- Hyperkalemia

## Interventions

- **DRUG:** Sodium Zirconium Cyclosilicate (SZC)
- **DRUG:** SZC Placebo

## Key facts

- **NCT ID:** NCT04847232
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-30
- **Primary completion:** 2024-03-07
- **Final completion:** 2024-03-07
- **Target enrollment:** 2690 (ACTUAL)
- **Why stopped:** The event rate observed in the study continued to be below primary assumptions, so that the completion of the study within a reasonable timeframe was deemed very unlikely.
- **Last updated:** 2025-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04847232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04847232, "Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04847232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*